Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Summary. - Background: Fluorouracil-based chemoradiotherapy is regarded as a standard perioperative treatment in locally advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug capecitabine. Methods: This randomised, open-label, multicentre,...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 2012
|
| In: |
The lancet. Oncology
Year: 2012, Volume: 13, Issue: 6, Pages: 579-588 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(12)70116-X |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(12)70116-X Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S147020451270116X 
|
| Author Notes: | Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, Axel Matzdorff, Stephan Laechelt, Jörg T Hartmann, Lothar Müller, Hartmut Link, Markus Moehler, Erika Kettner, Elisabeth Fritz, Udo Hieber, Hans Walter Lindemann, Martina Grunewald, Stephan Kremers, Christian Constantin, Matthias Hipp, Gernot Hartung, Deniz Gencer, Peter Kienle, Iris Burkholder, Andreas Hochhaus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580054870 | ||
| 003 | DE-627 | ||
| 005 | 20230427065640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180815s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(12)70116-X |2 doi | |
| 035 | |a (DE-627)1580054870 | ||
| 035 | |a (DE-576)510054870 | ||
| 035 | |a (DE-599)BSZ510054870 | ||
| 035 | |a (OCoLC)1341016878 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer |b a randomised, multicentre, non-inferiority, phase 3 trial |c Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, Axel Matzdorff, Stephan Laechelt, Jörg T Hartmann, Lothar Müller, Hartmut Link, Markus Moehler, Erika Kettner, Elisabeth Fritz, Udo Hieber, Hans Walter Lindemann, Martina Grunewald, Stephan Kremers, Christian Constantin, Matthias Hipp, Gernot Hartung, Deniz Gencer, Peter Kienle, Iris Burkholder, Andreas Hochhaus |
| 264 | 1 | |c June 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.08.2018 | ||
| 520 | |a Summary. - Background: Fluorouracil-based chemoradiotherapy is regarded as a standard perioperative treatment in locally advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug capecitabine. Methods: This randomised, open-label, multicentre, non-inferiority, phase 3 trial began in March, 2002, as an adjuvant trial comparing capecitabine-based chemoradiotherapy with fluorouracil-based chemoradiotherapy, in patients aged 18 years or older with pathological stage II-III locally advanced rectal cancer from 35 German institutions. Patients in the capecitabine group were scheduled to receive two cycles of capecitabine (2500 mg/m2 days 1-14, repeated day 22), followed by chemoradiotherapy (50·4 Gy plus capecitabine 1650 mg/m2 days 1-38), then three cycles of capecitabine. Patients in the fluorouracil group received two cycles of bolus fluorouracil (500 mg/m2 days 1-5, repeated day 29), followed by chemoradiotherapy (50·4 Gy plus infusional fluorouracil 225 mg/m2 daily), then two cycles of bolus fluorouracil. The protocol was amended in March, 2005, to allow a neoadjuvant cohort in which patients in the capecitabine group received chemoradiotherapy (50·4 Gy plus capecitabine 1650 mg/m2 daily) followed by radical surgery and five cycles of capecitabine (2500 mg/m2 per day for 14 days) and patients in the fluorouracil group received chemoradiotherapy (50·4 Gy plus infusional fluorouracil 1000 mg/m2 days 1-5 and 29-33) followed by radical surgery and four cycles of bolus fluorouracil (500 mg/m2 for 5 days). Patients were randomly assigned to treatment group in a 1:1 ratio using permuted blocks, with stratification by centre and tumour stage. The primary endpoint was overall survival; analyses were done based on all patients with post-randomisation data. Non-inferiority of capecitabine in terms of 5-year overall survival was tested with a 12·5% margin. This trial is registered with ClinicalTrials.gov, number NCT01500993. Findings: Between March, 2002, and December, 2007, 401 patients were randomly allocated; 392 patients were evaluable (197 in the capecitabine group, 195 in the fluorouracil group), with a median follow-up of 52 months (IQR 41-72). 5-year overall survival in the capecitabine group was non-inferior to that in the fluorouracil group (76% [95% CI 67-82] vs 67% [58-74]; p=0·0004; post-hoc test for superiority p=0·05). 3-year disease-free survival was 75% (95% CI 68-81) in the capecitabine group and 67% (59-73) in the fluorouracil group (p=0·07). Similar numbers of patients had local recurrences in each group (12 [6%] in the capecitabine group vs 14 [7%] in the fluorouracil group, p=0·67), but fewer patients developed distant metastases in the capecitabine group (37 [19%] vs 54 [28%]; p=0·04). Diarrhoea was the most common adverse event in both groups (any grade: 104 [53%] patients in the capecitabine group vs 85 [44%] in the fluorouracil group; grade 3-4: 17 [9%] vs four [2%]). Patients in the capecitabine group had more hand-foot skin reactions (62 [31%] any grade, four [2%] grade 3-4 vs three [2%] any grade, no grade 3-4), fatigue (55 [28%] any grade, no grade 3-4 vs 29 [15%], two [1%] grade 3-4), and proctitis (31 [16%] any grade, one [<1%] grade 3-4 vs ten [5%], one [<1%] grade 3-4) than did those in the fluorouracil group, whereas leucopenia was more frequent with fluorouracil than with capecitabine (68 [35%] any grade, 16 [8%] grade 3-4 vs 50 [25%] any grade, three [2%] grade 3-4). Interpretation: Capecitabine could replace fluorouracil in adjuvant or neoadjuvant chemoradiotherapy regimens for patients with locally advanced rectal cancer. Funding: Roche Pharma AG (Grenzach-Wyhlen, Germany). | ||
| 700 | 1 | |a Wenz, Frederik |d 1966- |e VerfasserIn |0 (DE-588)113310390 |0 (DE-627)663837766 |0 (DE-576)346656281 |4 aut | |
| 700 | 1 | |a Post, Stefan |d 1954- |e VerfasserIn |0 (DE-588)1026227518 |0 (DE-627)726294667 |0 (DE-576)371524598 |4 aut | |
| 700 | 1 | |a Gencer, Deniz |d 1980- |e VerfasserIn |0 (DE-588)140107940 |0 (DE-627)616027850 |0 (DE-576)314627332 |4 aut | |
| 700 | 1 | |a Kienle, Peter |d 1966- |e VerfasserIn |0 (DE-588)1030310262 |0 (DE-627)735023476 |0 (DE-576)378115898 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 13(2012), 6, Seite 579-588 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer a randomised, multicentre, non-inferiority, phase 3 trial |
| 773 | 1 | 8 | |g volume:13 |g year:2012 |g number:6 |g pages:579-588 |g extent:10 |a Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer a randomised, multicentre, non-inferiority, phase 3 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(12)70116-X |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S147020451270116X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180815 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1030310262 |a Kienle, Peter |m 1030310262:Kienle, Peter |d 60000 |d 50000 |e 60000PK1030310262 |e 50000PK1030310262 |k 0/60000/ |k 0/50000/ |p 20 | ||
| 998 | |g 140107940 |a Gencer, Deniz |m 140107940:Gencer, Deniz |d 60000 |d 65500 |e 60000PG140107940 |e 65500PG140107940 |k 0/60000/ |k 1/60000/65500/ |p 19 | ||
| 998 | |g 1026227518 |a Post, Stefan |m 1026227518:Post, Stefan |d 60000 |d 61800 |e 60000PP1026227518 |e 61800PP1026227518 |k 0/60000/ |k 1/60000/61800/ |p 3 | ||
| 998 | |g 113310390 |a Wenz, Frederik |m 113310390:Wenz, Frederik |d 60000 |d 63000 |e 60000PW113310390 |e 63000PW113310390 |k 0/60000/ |k 1/60000/63000/ |p 2 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 65500 |e 60000PH121917517 |e 65500PH121917517 |k 0/60000/ |k 1/60000/65500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1580054870 |e 3022377533 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer","title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer","subtitle":"a randomised, multicentre, non-inferiority, phase 3 trial"}],"language":["eng"],"name":{"displayForm":["Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, Axel Matzdorff, Stephan Laechelt, Jörg T Hartmann, Lothar Müller, Hartmut Link, Markus Moehler, Erika Kettner, Elisabeth Fritz, Udo Hieber, Hans Walter Lindemann, Martina Grunewald, Stephan Kremers, Christian Constantin, Matthias Hipp, Gernot Hartung, Deniz Gencer, Peter Kienle, Iris Burkholder, Andreas Hochhaus"]},"person":[{"display":"Hofheinz, Ralf-Dieter","role":"aut","given":"Ralf-Dieter","family":"Hofheinz"},{"family":"Wenz","given":"Frederik","role":"aut","display":"Wenz, Frederik"},{"display":"Post, Stefan","role":"aut","given":"Stefan","family":"Post"},{"family":"Gencer","given":"Deniz","role":"aut","display":"Gencer, Deniz"},{"family":"Kienle","display":"Kienle, Peter","role":"aut","given":"Peter"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"June 2012"}],"recId":"1580054870","id":{"eki":["1580054870"],"doi":["10.1016/S1470-2045(12)70116-X"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"disp":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer a randomised, multicentre, non-inferiority, phase 3 trialThe lancet. Oncology","id":{"eki":["325349770"],"zdb":["2035574-9"],"issn":["1474-5488"]},"note":["Gesehen am 22.09.2021"],"titleAlt":[{"title":"The lancet <London> / Oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"325349770","origin":[{"dateIssuedDisp":"2000-","publisher":"The Lancet Publ. Group","dateIssuedKey":"2000","publisherPlace":"London"}],"pubHistory":["0.2000 -"],"title":[{"title_sort":"lancet","partname":"Oncology","title":"The lancet"}],"language":["eng"],"part":{"issue":"6","pages":"579-588","extent":"10","year":"2012","text":"13(2012), 6, Seite 579-588","volume":"13"}}],"note":["Gesehen am 15.08.2018"]} | ||
| SRT | |a HOFHEINZRACHEMORADIO2012 | ||